Abacavir Substitution for Nucleoside Analogs in Patients With HIV LipoatrophyA Randomized Trial | Zendy

Andrew Carr | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Abacavir Substitution for Nucleoside Analogs in Patients With HIV Lipoatrophy<SUBTITLE>A Randomized Trial</SUBTITLE>

Author(s) -

Andrew Carr

Publication year - 2002

Publication title -

jama

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.688

H-Index - 680

eISSN - 1538-3598

pISSN - 0098-7484

DOI - 10.1001/jama.288.2.207

Subject(s) - stavudine , abacavir , lipoatrophy , medicine , zidovudine , lipodystrophy , didanosine , lamivudine , mitochondrial toxicity , gastroenterology , surgery , viral load , virology , antiretroviral therapy , human immunodeficiency virus (hiv) , viral disease , virus , hepatitis b virus , toxicity

Peripheral lipoatrophy may complicate antiretroviral therapy of human immunodeficiency virus (HIV) infection, often related to duration and type of nucleoside analog therapy, and may have a mitochondrial pathogenesis. No proven therapy exists for lipoatrophy, but abacavir is a nucleoside analog that may be less toxic to mitochondria.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research